Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Piper Sandler

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster.

Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings

Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings

Piper Sandler raised the price target marginally on Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to $8.75 from $8.00, with an Overweight rating unchanged. Catalyst expects FY22 revenue of $195 million - $205 million, driven by transitioning ~125 patients previously on Ruzurgi onto Firdapse, analyst Joseph Catanzaro writes in a research note. Wall Street's estimate for sales…

China's Lockdown Of Tech Hubs To Hamper Amazon, Walmart's Online Delivery: Report

China's Lockdown Of Tech Hubs To Hamper Amazon, Walmart's Online Delivery: Report

China's recent lockdown looks to hamper the online order delivery of global e-commerce firms like Amazon.com Inc (NASDAQ:AMZN) and Walmart Inc (NYSE:WMT), Bloomberg reports. China had to initiate lockdowns and restrictions in its crucial manufacturing hubs like Shenzhen and Dongguan following a Covid-19 resurgence. Related Content: China Restricts Activities In Shenzhen, Shanghai Following Covid-19 Resurgence The…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

KeyBanc Remains Upbeat On Apple Citing iPhone SE 3; BofA, Piper Sandler See Limited Impact From China Lockdown

KeyBanc's Key First Look Data suggested that Apple Inc (NASDAQ: AAPL) tracked slightly better than historical seasonality. The indexed spending was down (9)% month-on-month in February, beating the 3-year average decline of (13)%.

Piper Sandler Cuts Ameresco Price Target By 20%

Ameresco Inc (NYSE:AMRC) price target was lowered to $64 (a downside of 7%) from $80 by Piper Sandler analyst Kashy Harrison. The analyst maintained the Neutral rating on Ameresco shares. Harrison noted that European demand for non-Russian energy supply will "skyrocket." He thinks that the Ukraine crisis boosts demand for renewables/alternatives and is positive for…

Analysts Slash Their PTs On Oracle As They Did Not Buy Its Growth Story

Analysts slashed their price targets on Oracle Corp (NYSE:ORCL) post Q3 results. Piper Sandler analyst Brent Bracelin downgraded to Underweight from Neutral with a PT of $70 (8.7% downside), down from $100. Bracelin found it challenging to reach double-digit organic growth next year, sustaining a cloud shift considering more than 70% of revenue came from the…

Piper Sandler Remains Cautious On Tesla Despite Noting Its Strength

Piper Sandler analyst Alexander Potter admitted that the current weekly China Passenger Car Association February sales and production exhibited continued strength for Tesla Inc's (NASDAQ:TSLA) Shanghai factory. Tesla sold 56,515 China-made vehicles in February, including 33,315 for export. Potter also noticed a "general uptick in inbound calls" from investors regarding Tesla's exposure to geopolitical risks and commodity price…

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Palantir Shares Are Ripping Higher

Why Palantir Shares Are Ripping Higher

Palantir Technologies Inc (NYSE: PLTR) is surging Wednesday after Piper Sandler analyst Weston Twigg initiated coverage on the stock with an Overweight rating and a $15 price target.

Analysts Continue To See Sharp Upside In Bumble Post Q4

Analysts Continue To See Sharp Upside In Bumble Post Q4

Analysts continue to see sharp upside in Bumble Inc (NASDAQ:BMBL) despite cutting their price targets post Q4 results. BMO Capital analyst Daniel Salmon upgraded to Outperform from Market Perform with an unchanged price target of $48 (103% upside). Online dating is poised to outperform the internet sector. Cowen analyst John Blackledge raised the price target to $38…

Why This Data Analytics Company's 'High Growth' Will Likely Continue

Why This Data Analytics Company's 'High Growth' Will Likely Continue

Palantir Technologies Inc. (NYSE: PLTR), while being controversial, has set its sights on achievable growth targets, according to an analyst at Piper Sandler.

Piper Sandler Slashes Facebook Parent Meta's Price Target By 20%; Reiterates Overweight

Piper Sandler Slashes Facebook Parent Meta's Price Target By 20%; Reiterates Overweight

Piper Sandler cut its price target on the Meta Platforms Inc (NASDAQ: FB), noting that its advertising headwinds are likely to continue for several months. Analyst Thomas Champion lowered his price target to $240 from $301, implying a 28% upside.

Evolent Health 'Notification Award' Removes $82M Overhang, Notes Piper Sandler

Evolent Health 'Notification Award' Removes $82M Overhang, Notes Piper Sandler

In an SEC filing, Cook County named Evolent Health Inc (NYSE:EVH) the sole third-party administrator for CountyCare Health Plan from fiscal 2023 through fiscal 2025. Piper Sandler analyst Jessica Tassan notes that the award extends a contract Evolent has held since fiscal 2018 to provide administrative simplification services to support CountyCare's 425,000 Medicaid…

Analysts Move To Sidelines On Vicarious Surgical After Regulatory Update

Analysts Move To Sidelines On Vicarious Surgical After Regulatory Update

Piper Sandler has downgraded Vicarious Surgical Inc (NASDAQ:RBOT) to Neutral from Overweight with a price target of $7, down from $16, below expected Q4 results. A majority of the earnings call focused on the Company's regulatory update. Vicarious announced its plans to pursue a De Novo FDA pathway, including a pre-market study, for its…

Analysts Cut Price Target On Aziyo Biologics As Q4 Earnings Fall Short Of Expectations

Analysts Cut Price Target On Aziyo Biologics As Q4 Earnings Fall Short Of Expectations

Aziyo Biologics Inc (NASDAQ:AZYO) Q4 FY21 sales decreased 13% to $10.9 million, missing the consensus of $11.06 million. Excluding the contribution of FiberCel sales, which the product's distributor discontinued in Q2 of 2021, Q4 sales increased 6% Y/Y. The 510(k) application for CanGaroo RM, the Company's next-generation envelope, remains on track for submission…

Get all your
news in one place.

100's of premium titles.
One news app.

10 Biggest Price Target Changes For Thursday

Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% to $2.59 in pre-market trading.

Read How Analysts Reacted To Salesforce's Q4 Results

Analysts adjusted their price targets on Salesforce.com Inc (NYSE:CRM) post Q4 results. Citi analyst Tyler Radke raised the firm's price target on Salesforce to $233 from $220 (11.5% upside) and kept a Neutral. The company "delivered a reassuring" Q4 and outlook, which should help alleviate concerns around the health of the front office and general…

Piper Sandler Remains Optimistic About Broadcom, Thanks To Apple

Piper Sandler analyst Harsh Kumar believes Broadcom Inc (NASDAQ: AVGO) is in a "great position to beat and raise" when it reports earnings later this week.

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Analysts Continue To See Sharp Upside In Sprout Social Post Q4 Results

Analysts cut their price targets on Sprout Social Inc (NASDAQ:SPT) post Q4 results. Needham analyst Scott Berg lowered the price target to $75 from $160 (37% upside) given the significant multiple compression across high growth software but kept a Buy. The company's Q4 results were "impressive," highlighted by the acceleration of upmarket demand, record large…

Piper Sandler Upgrades Marathon Oil After Strong Management Message

Marathon Oil Corporation (NYSE: MRO) expects to return up to $3.1 billion to shareholders in 2022, which equates to around 20% of its shares outstanding, according to Piper Sandler.

Read How Analysts Reacted To Aspen Aerogels' Q4 Results

H.C. Wainwright analyst Amit Dayal lowered the price target on Aspen Aerogels Inc (NYSE:ASPN) to $45 (an upside of 57.6%) from $65 and maintained a Buy rating on the shares. The analyst cites the company's updated outlook stemming from plans for its thermal runaway expansion for the target drop. Though Aspen's mid-term expectation of hitting…

Read How Analysts Reacted To Alteryx's Q4 Results

Analysts had mixed opinions on Alteryx Inc (NYSE:AYX) post Q4 beat. Alteryx is a software company that provides self-service data analytics software. Oppenheimer analyst Ittai Kidron lowered the firm's price target on Alteryx to $85 from $105 (62.9% upside) to reflect multiple realignments while keeping an Outperform rating on the shares. The analyst notes Alteryx's Q4…

Here's Why Piper Sandler Is Optimistic On Nvidia

Piper Sandler analyst Harsh Kumar reiterated an Overweight rating and $350 price target on NVIDIA Corp (NASDAQ:NVDA). Nvidia could be a big winner this earnings season, with profits driven by solid performance in the chip maker's gaming and data center businesses, Kumar said. "We are looking for a significant beat and raise when the company…

Tesla Shares Continue To Hold Strong In A Pattern: What's Next?

Tesla Inc. (NASDAQ: TSLA) shares are trading higher Monday. The stock is trading in a bullish reversal pattern and looks to have recently bounced off the 200-day support level. Piper Sandler maintained an Overweight rating on the stock and raised the price target to $1,350.

Why Are HubSpot Shares Trading Higher Today?

Analysts mainly hailed HubSpot Inc's (NYSE:HUBS) Q4 performance by raising their price targets on the stock. Mizuho analyst Siti Panigrahi raised the price target on HubSpot to $625 from $500 (16.92% upside) and kept a Buy rating on the shares. The company reported strong results once again in Q4 on broad-based strength with a particular…

1 … 14 15 16 17

People

Thomas Champion

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Amazon.com Inc.

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

398,619 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play